Abstract
This thesis investigates the possible advantages of a new stent technology that aims to improve care for patients with coronary artery disease. The COMBO stent (OrbusNeich Medical BV, The Netherlands) contains a dual-therapy stent technology. The stent combines two techniques: a sirolimus-elution with an added anti-CD34+ antibody layer for rapid endothelialisation of the stent. This anti-body layer captures circulating endothelial progenitor cells (EPCs) that can bind to the stent surface. These cells will hereafter differentiate on the stent surface into normal endothelial cells, rapidly forming a normal endothelial layer. Therefore this stent technique might safely allow a shorter duration of dual-antiplatelet therapy.
This thesis focuses on clinical outcomes in patients treated with COMBO stent from the investigator-initiated, prospective, European, 1000 all-comers patients REMEDEE Registry.
This thesis focuses on clinical outcomes in patients treated with COMBO stent from the investigator-initiated, prospective, European, 1000 all-comers patients REMEDEE Registry.
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Awarding Institution | |
Supervisors/Advisors |
|
Award date | 6 Jun 2018 |
Print ISBNs | 9789462999497 |
Publication status | Published - 2018 |